Cover Image
市場調查報告書

蕈狀肉芽腫開發中產品分析

Mycosis Fungoides - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 271835
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
蕈狀肉芽腫開發中產品分析 Mycosis Fungoides - Pipeline Review, H2 2014
出版日期: 2014年10月25日 內容資訊: 英文 65 Pages
簡介

本報告提供對蕈狀肉芽腫的治療藥的開發情形調查分析、開發中產品的概要、臨床實驗各階段的產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等,為您概述為以下內容。

目錄

簡介

蕈狀肉芽腫概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

正在開發的治療藥:各大學/實驗室

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • 鹽野義製藥
  • Sanofi
  • Seattle Genetics, Inc.
  • Echo Therapeutics, Inc.

治療藥的評估

  • 單獨療法的情況
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • interferon gamma-1a
  • brentuximab vedotin
  • mechlorethamine hydrochloride
  • alemtuzumab
  • methotrexate
  • NSC-678515
  • 基因改造T細胞-1138
  • CIGB-128 - Drug Profile

開發中產品的最新趨勢

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5634IDB

Summary

Global Markets Direct's, 'Mycosis Fungoides - Pipeline Review, H2 2014', provides an overview of the Mycosis Fungoides's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mycosis Fungoides, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycosis Fungoides and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mycosis Fungoides
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mycosis Fungoides and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mycosis Fungoides pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mycosis Fungoides
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mycosis Fungoides pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mycosis Fungoides Overview
  • Therapeutics Development
    • Pipeline Products for Mycosis Fungoides - Overview
    • Pipeline Products for Mycosis Fungoides - Comparative Analysis
  • Mycosis Fungoides - Therapeutics under Development by Companies
  • Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes
  • Mycosis Fungoides - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Mycosis Fungoides - Products under Development by Companies
  • Mycosis Fungoides - Products under Investigation by Universities/Institutes
  • Mycosis Fungoides - Companies Involved in Therapeutics Development
    • Sanofi
    • Seattle Genetics, Inc.
    • Echo Therapeutics, Inc.
    • Actelion Ltd
  • Mycosis Fungoides - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • brentuximab vedotin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mechlorethamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alemtuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methotrexate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NSC-678515 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CIGB-128 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mycosis Fungoides - Recent Pipeline Updates
  • Mycosis Fungoides - Product Development Milestones
    • Featured News & Press Releases
      • Apr 08, 2014: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS in Key Countries
      • Nov 18, 2013: Actelion launches VALCHLOR gel 0.016% in the US
      • Jan 30, 2013: Ceptaris Announces Publication In JAMA Dermatology Of Positive Clinical Results For Mechlorethamine Gel In Early Stage Mycosis Fungoides
      • Nov 26, 2012: Seattle Genetics Receives FDA Orphan Drug Designation For Adcetris To Treat Mycosis Fungoides
      • Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel
      • Oct 04, 2011: FDA Accepts Filing Of NDA For Yaupongel's Gel Formulation Of Mechlorethamine Hydrochloride
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mycosis Fungoides, H2 2014
  • Number of Products under Development for Mycosis Fungoides - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Mycosis Fungoides - Pipeline by Sanofi, H2 2014
  • Mycosis Fungoides - Pipeline by Seattle Genetics, Inc., H2 2014
  • Mycosis Fungoides - Pipeline by Echo Therapeutics, Inc., H2 2014
  • Mycosis Fungoides - Pipeline by Actelion Ltd, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Mycosis Fungoides Therapeutics - Recent Pipeline Updates, H2 2014

List of Figures

  • Number of Products under Development for Mycosis Fungoides, H2 2014
  • Number of Products under Development for Mycosis Fungoides - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top